Immunopathogenic Endotypes of Asthma: From Type 2 and Non-Type 2 Inflammation to Precision Therapeutic Strategies.

Xolair (omalizumab) - Roche, Novartis

Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen

Nucala (mepolizumab) - GSK

Dupixent (dupilumab) - Sanofi, Regeneron

http://www.ncbi.nlm.nih.gov/pubmed/42773570

Krishna R Gupta; Milind J Umekar; Pradip S More; Uma D Kabra

Sep 24, 2026